Home » Stocks » Relay Therapeutics

Relay Therapeutics, Inc. (RLAY)

Stock Price: $40.27 USD 1.99 (5.20%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 3.62B
Revenue (ttm) n/a
Net Income (ttm) -83.33M
Shares Out 89.97M
EPS (ttm) -0.93
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 22, 2020
Last Price $40.27
Previous Close $38.28
Change ($) 1.99
Change (%) 5.20%
Day's Open 38.35
Day's Range 38.35 - 40.79
Day's Volume 131,252
52-Week Range 32.56 - 49.89

More Stats

Market Cap 3.62B
Enterprise Value 3.33B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 89.97M
Float 42.33M
EPS (basic) n/a
EPS (diluted) -0.93
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 5.09M
Short Ratio 8.72
Short % of Float 12.03%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 10.52
Revenue n/a
Operating Income n/a
Net Income -83.33M
Free Cash Flow n/a
Net Cash 288.84M
Net Cash / Share 3.21
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 3
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(22.50% upside)
Current: $40.27
Target: 49.33
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-84.05-49.89
Net Income-75.31-48.79
Shares Outstanding3.452.49
Earnings Per Share-21.82-19.63
Operating Cash Flow-66.13-44.14
Capital Expenditures-7.98-1.68
Free Cash Flow-74.12-45.82
Cash & Equivalents357422
Total Debt24.830.18
Net Cash / Debt332422
Book Value-180-111
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Relay Therapeutics, Inc.
Country United States
Employees 123
CEO Sanjiv K. Patel

Stock Information

Ticker Symbol RLAY
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: RLAY
IPO Date July 16, 2020


Relay Therapeutics operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its product candidates include RLY-1971, an oral small molecule inhibitor of the protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 (SHP2) that is in Phase 1 dose escalation studies in patients with advanced or metastatic solid tumors; RLY-4008, an oral small molecule selective inhibitor of fibroblast growth factor receptor 2 (FGFR2) for patients with advanced solid tumors having oncogenic FGFR2 alterations; and RLY-PI3K1047, a lead compound that targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.